Giselle Mosnaim, MD, discusses the epidemiology that is associated with CSU.
Video content above is prompted by the following question(s):
Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis
February 6th 2026Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.
Read More